HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Military Report Slams DMAA While GNC Claims Victory

This article was originally published in The Tan Sheet

Executive Summary

A Department of Defense safety review panel does not find a conclusive causal association between DMAA and adverse events, including four service members’ deaths, a conclusion that “delighted” retailer GNC. But DoD’s ban on sales of DMAA products in military exchanges and concessions remains in place.

You may also be interested in...



In Brief

FDA seeks DMAA product seizure; skin tag remover study flawed – ERSP; Plan B One-Step approved fully OTC; FDA continues evaluating laxative TEA; FDA hosts supply chain public hearing; energy drink marketing to youths challenged; more news In Brief.

FDA Using “All Available Tools” To Remove DMAA From Market

FDA issues a consumer warning about the potentially lethal effects of DMAA, and promises to use “all available tools at its disposal to ensure the dietary supplements containing” the stimulant “are no longer distributed and available for sale.”

DMAA Supplements Banned In U.K., Hamstrung In U.S.

The Medicines and Healthcare products Regulatory Agency bans use of dimethylamylamine in the United Kingdom. Meanwhile, FDA has stopped short of an all-out ban, though retailers and insurance carriers largely have turned their backs on DMAA.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS124277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel